Obesity and Cancer
Release Date: January 01, 2019
Expiration Date: December 31, 2020
This educational activity is provided by Dannemiller
Supported by an educational grant from Novo Nordisk Inc.
Physicians, Nurse Practitioners, Registered Dietitians, Registered Nurses.
Upon completion of this activity, the participant should be able to:
- To review the evidence linking lifestyle factors to cancer outcomes
- To review the randomized trials of lifestyle change in cancer survivors and discuss on-going work in this area
- To discuss the American Society of Clinical Oncology Obesity Initiative and other efforts to help cancer survivors adopt healthy lifestyles after cancer diagnosis
Statement of Need
As the obesity epidemic progresses, health care professionals should look toward educational forums to learn about the most modern advances in research, treatment, and best business practices to improve the quality of life for individuals who are obese and overweight. The conference promotes educational advancement by merging academic and clinical experts with professionals, and provides an opportunity for networking and the exchange of indispensable knowledge.
Method of Participation
This activity should take approximately one hour to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through December 31, 2020. No credit will be given after this date. There is no fee to participate in this activity.
In the event you have questions about this activity or are unable to retrieve the certificate, please email firstname.lastname@example.org and a certificate will be emailed within 2 weeks.
- Computer, tablet, or smartphone with internet access
- HTML5 compatible browser or Adobe Flash Player
In support of improving patient care, Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 090419. This program is accredited for 1.0 contact hours.
Dannemiller is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Crendentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this material CDR Provider #DM002. Level 2 Activity
Dannemiller designates this educational activity for 1.00 contact hours.
Jennifer Ligibel, MD
Associate Professor, Medicine
Harvard Medical School Senior Physician Dana-Farber Cancer Institute
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
The following faculty stated they have no relevant financial disclosure:
- Jennifer Ligibel, MD
The content reviewer and Jennifer Hodge, Dannemiller project manager, have no financial relationships with commercial interests.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.